Gold
| Address | 14F KTB Bldg. 66, Yeoui-daero, Yeongdeungpo-gu, Seoul, Korea | ||
|---|---|---|---|
| Telephone | +82-2-784-5300 | Fax | +82-2-786-8368 |
| Website | www.illumina.com | techsupport@illumina.com | |
Advancements in our understanding of genetics have the potential to change the practice of medicine and enable genomics-based healthcare. With streamlined workflows and advanced informatics, Illumina sequencing and array technologies and analysis services are allowing you to explore the genome more than ever before. Together, we can address healthcare in ways never before imagined. Visit the Illumina booth to find out how.
The TruSight™ Oncology 500 product family enables comprehensive genomic profiling (CGP) from both blood and tissue biopsy samples in house. All three assays are designed to analyze 523 cancer-relevant genes and identify key biomarkers in guidelines in clinical trials.
The NextSeq™ 550Dx instrument is a FDA regulated, CE-IVD marked and MFDS registered high-throughput sequencing platform to the clinical research laboratory. The instrument includes a Diagnostic Mode (Dx Mode) and a Research Mode, which provides the flexibility to perform IVD testing, LDT development, and clinical research on a single instrument.
The NovaSeq 6000 System provides access to a powerful, high throughput genomics solution that empowers users to perform studies at the throughput and price per sample that meets their research objectives.
